Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutations.

Lipids - 1 Dec 2014

Niesor Eric J, Kallend David, Bentley Darren, Kastelein John J P, Kees Hovingh G, Stroes Erik S G

Abstract excerpt

We investigated the effect of dalcetrapib treatment on phytosterol levels in patients with familial combined hyperlipidemia (FCH) or familial hypoalphalipoproteinemia (FHA) due to mutations in apolipoprotein A1 (ApoA1) or ATP-binding cassette transporter A1 (ABCA1). Patients (n = 40) with FCH or FHA received dalcetrapib 600 mg or placebo in this 4-week, double-blind, crossover study. Lipids, apolipoproteins,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Apolipoprotein A-I

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter 1

Share to Cholesterol Ester Transfer Proteins

Share to Cross-Over Studies

Share to Esters

Share to Phytosterols

Share to Sulfhydryl Compounds

Source

Identifiers

PMID: 25281277
DOI: 10.1007/s11745-014-3956-x

Genes

ABCA1
CETP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutations.PMID 25281277Read ↗

Phytosterol Enriched Food Supplements for Plasma LDL-Cholesterol Lowering: Yes or No?Semantic proximity Read ↗

Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease.Semantic proximity Read ↗

Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial.Semantic proximity Read ↗

Cosegregation of serum cholesterol with cholesterol intestinal absorption markers in families with primary hypercholesterolemia without mutations in LDLR, APOB, PCSK9 and APOE genes.Semantic proximity Read ↗

Cholesteryl Ester Transfer Protein Inhibition and High-Density Lipoprotein Particle Composition: Consequences for Atherogenesis and NeurodegenerationSemantic proximity Read ↗

Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.Semantic proximity Read ↗

Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia: role of the ABCA1 gene mutations.Semantic proximity Read ↗

Lomitapide affects HDL composition and function.Semantic proximity Read ↗

Plasma non-cholesterol sterols in primary hypobetalipoproteinemia.Semantic proximity Read ↗

Increased intestinal cholesterol absorption in autosomal dominant hypercholesterolemia and no mutations in the low-density lipoprotein receptor or apolipoprotein B genes.Semantic proximity Read ↗

MTP gene polymorphisms and postprandial lipemia in familial combined hyperlipidemia: effects of treatment with atorvastatin.Semantic proximity Read ↗

Effects of dietary cholesterol and fat on serum non-cholesterol sterols according to different apolipoprotein E subgroups among healthy men.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.